To evaluate the short- and long-term safety profile of IL-17 or IL-23 inhibitors, we conducted this systematic review and meta-analysis, which assessed the short-term risk and long-term incidence rate of (1) overall infection, (2) serious infection, (3) malignancy, (4) nasopharyngitis, (5) upper respiratory tract infection, (6) Candida infection, (7) tuberculosis, (8) hepatitis, and (9) herpes zoster with IL-17 inhibitors and IL-23 inhibitors in adult patients with PsO or PsA. Here, IL17A is linked to Recurrent upper respiratory tract infections.